Company
Headquarters: Chongqing, China
Employees: 935
CN¥2.54 Billion
CNY as of July 1, 2024
US$349.9 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
| AbbVie | $295.34 B |
| AstraZeneca | $236.45 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Chongqing Lummy Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products in China. The company provides tumor, antibacterial, antiviral, and antifungal, as well as liver disease auxiliary, endocrinology system, and Chinese patent drugs; digestive system, immune system, blood system, cardiovascular system, and nervous system drugs; electrolyte and acid-base products; balance and nutritional products; and base large infusion products, American ginseng systems, and active pharmaceutical ingredients. Chongqing Lummy Pharmaceutical Co., Ltd. was founded in 1999 and is based in Chongqing, China.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Chongqing Lummy Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300006 wb_incandescent